Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
Status:
Completed
Trial end date:
2020-05-27
Target enrollment:
Participant gender:
Summary
This study was a phase III, multicenter, triple-blind, equivalency clinical trial to
determine the therapeutic efficacy and safety between Pertuzumab® (CinnaGen Co.) compared to
originator pertuzumab in HER2-positive early breast cancer patients.
Patients were stratified dynamically for random assignment to treatment with either
Pertuzumab® (CinnaGen Co.) or originator pertuzumab, and received neoadjuvant TCHP regimen
every 3- weeks.